In the future, the use of sunitinib or sorafenib may find an application, as these are the clinically approved drugs that may be combined with radiotherapy, while, in model systems, both acted as HIF-1a suppressors and radiosensitizers of hypoxic cancer cells (see Table 1 and [96,97]). The gene discussed is HIF1A; the disease is cancer.